Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography

What Was Tested

The paper reports a study of Somatostatin and Lanreotide, published as a clinical trial.

Positron emission tomography (PET) of (68)Ga-radiolabelled (SST) somatostatin receptor (R) binding peptides has recently been evaluated in SSTR positive tumor patients.

The researchers report their first experience with (68)Ga-labeled DOTA-LAN.

Who Took Part

The abstract describes 3 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Eleven patients (3 non small cell lung cancer [NSCLC], 3 small cell lung cancer [SCLC], 3 radioiodine negative thyroid cancer, 2 medullary thyroid cancer [MTC]) were investigated.

After intravenous injection of 75-150 MBq (68)Ga-DOTA-LAN dynamic studies were acquired over the tumor site for the first 40 min with a dedicated PET scanner in 3 patients, and 2 partial body scans were acquired at 20 and 50 min p.i. in 2 patients.

How the Study Was Run

Whole body acquisitions at 90 min after injection were acquired in all 11 patients.

Image reconstruction was performed by iterative reconstruction utilizing additional transmission scans for attenuation correction.

Vital parameters were recorded during the PET study and up to 24 h p.i.

Blood and urinary sampling was done up to 4 hr after tracer injection in 8 patients.

PET results were compared to conventional imaging techniques (CIT), i.e. computed tomography (CT) and/or magnetic resonance imaging (MRI).

What Was Measured

Topics PubMed links to this paper include Amino Acid Sequence, Gallium Radioisotopes, Heterocyclic Compounds, 1-Ring, Image Interpretation, Computer-Assisted, Lung Neoplasms, Peptides, Cyclic and Positron-Emission Tomography.

What This Means in Plain Language

This is a clinical trial of Somatostatin and Lanreotide in 3 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...), a journal based in Italy.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.